Relationship of paraoxonase-1  Q192R  genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting

Ma, Wenfang; Liang, Yan; Zhu, Jun; Chen, Tao; Feng, Guangxun; Yang, Yanmin; Liu, Xin; Wang, Xingyu

doi:10.1016/j.atherosclerosis.2016.07.901

Cited by 13 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients carrying PON1 Q showed lower PON1 activity and a higher risk of stent thrombosis than PON1 R [12, 13]. Unlike CYP2C19 ∗ 2 or ∗ 3, the effect of PON1 on the response to clopidogrel was still controversial due to negative results of PON1 Q192R from some studies [14–18]. ATP-binding cassette B1 (ABCB1) may be involved in drug resistance by decreasing absorption of clopidogrel through intestinal endothelial membrane.…”

Section: Introductionmentioning

confidence: 99%

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

Peng

Shi

et al. 2019

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Objective. The objective of this study is to explore the relationships of the effects of CYP2C19 and PON1 Q192R polymorphism on the activity of clopidogrel and the risk of high platelet responsiveness (HPR) by thrombelastography in patients with acute coronary syndrome (ACS). Methods. 459 ACS patients with aspirin and clopidogrel were enrolled in this observational case control study from July 13, 2015, to November 11, 2017. The patients with <30% platelet inhibition were defined as HPR group, while the others were defined as normal platelet responsiveness (NPR) group. The genotypes distribution between the groups was assessed, and the clinical impact of genetic variants was investigated by comparing the relationship between the risk of HPR and genotypes including CYP2C19⁎2, CYP2C19⁎3, CYP2C19⁎17, ABCB1, and PON1. Results. Compared with CYP2C19⁎1/⁎1 wild type carriers, CYP2C19⁎2 and ⁎3 carriers showed a significant association with the lower platelet inhibition (P=0.048). The platelet inhibition in carriers of at least one CYP2C19 loss-of-function (LOF) alleles was obviously higher than noncarriers (P=0.031). The platelet inhibition of PON1 192R carriers was lower than PON1 192Q carriers (P=0.044). Patients with the CYP2C19⁎2 and ⁎3 alleles had a greater risk of HPR than CYP2C19 wild type carriers (adjusted P=0.018 and adjusted P=0.005). At least one PON1 192R carrier predicted a significantly higher risk of HPR than PON1 192Q carriers (adjusted P=0.021). Individual CYP2C19⁎17 and ABCB1 variants did not differ significantly between the two groups. Conclusions. CYP2C19 and PON1 Q192R variants influence ADP-induced platelet inhibition by thrombelastography (TEG) in ACS patients with clopidogrel. In addition, both LOF CYP2C19 and PON1 192R variants are independent risk factors of HPR, which is measured by the relative platelet inhibition.

show abstract

Section: Introductionmentioning

confidence: 99%

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

Peng

Shi

et al. 2019

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…These results are consistent with a previous study showing that the increases clopidogrel dose can reduce HPPR 22,23 and improve the clinical outcomes. 34 On the other hand, several studies have failed to verify the relationship between the CYP2C19 polymorphism, HPPR, and ISR, 24,25 and have failed to show that the increased clopidogrel dose could reduce the risk of ISR in the CYP2C19 LOF allele carriers. 26,27 These discrepancies might be attributed to the differences in ethnics, since the distribution of CYP2C19 alleles might differ between Caucasians and Asians.…”

Section: Discussionmentioning

confidence: 99%

“…22,23 Whether this approach could reduce the risk of ISR remains unclear. However, several studies have failed to verify the relationship between the CYP2C19 polymorphism, HPPR, and ISR, 24,25 or the increased clopidogrel dose could reduce the risk of ISR in the CYP2C19 LOF allele carriers. 26,27 In this cohort study, the potential effects of the CYP2C19 polymorphism and clopidogrel dosing on ISR were investigated.…”

Section: Introductionmentioning

confidence: 99%

<p>Impacts of <em>CYP2C19</em> Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients</p>

Zhang

Wang

Zhang

et al. 2020

DDDT

View full text Add to dashboard Cite

Objective: This retrospective cohort study is to analyze the impacts of CYP2C19 polymorphism and clopidogrel dosing on in-stent restenosis (ISR) after coronary stenting. Methods: Totally, 111 patients were included, who underwent percutaneous coronary intervention (PCI) with drug-eluting stent. Patients received clopidogrel treatment after the intervention on the background treatment with aspirin, based on the genotypes: 75 mg clopidogrel once each day for subjects without CYP2C19 loss-of-function (LOF) alleles (n=51; EM), 75 mg clopidogrel once each day (n=27; IM75) or twice each day (n=33; IM150) for subjects with one CYP2C19 LOF allele. ISR at 3-18 months after coronary stenting was assessed. Results: ISR rate was significantly higher in the IM75 group (40.7%) than the EM group (11.8%). ISR rate in the IM150 group was lower than the IM75 group (6.1% vs 40.7%), and comparable to that in the EM group. Multivariate logistic regression showed that both CYP2C19 genotype and clopidogrel dosing were associated with the risk of ISR after adjusting the relevant confounding factors. ISR risk was higher in the IM patients than the EM patients. Patients with clopidogrel dose of 75 mg once each day had significantly higher risk of ISR than those with the dose of 75 mg twice each day. Conclusion: Increased dose of clopidogrel may reduce the risk of ISR after PCI in CYP2C19 LOF allele(s) carriers. The presence of CYP2C19 LOF allele(s) increases the risk of ISR after stenting, which could be counteracted by the increased dose of clopidogrel.

show abstract

“…Logistic regression analysis was applied to assess the relationship between genotype and ISR risk. The independent variables examined were based on previous studies [16, 17]. A p value less than 0.05 was considered to indicate statistical significance.…”

Section: Methodsmentioning

confidence: 99%

Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention

Song

et al. 2019

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background It is well known that the genotype of ALDH2 is associated with coronary artery disease (CAD), and in-stent restenosis (ISR) is a primary complication of percutaneous coronary intervention (PCI), a primary recommended treatment for CAD. The aim of this study was to identify the relationship between aldehyde dehydrogenase 2 ( ALDH2 ) genotype and in-stent restenosis (ISR). Methods This study recruited 531 patients who were undergoing PCI at two Chinese hospitals from 2015 to 2017 and 183 were diagnosed with ISR after PCI during the one-year follow-up period. We used polymerase chain restriction fragment length polymorphism (PCR-RFLP) and sequencing to determine ALDH2 polymorphisms. Results Among all 531 patients (mean age = 59.4 ± 9.8; 65.9% male), 68.7% carried the wild-type genotype, 28.4% were heterozygous for the mutation, and 2.8% were homozygous for the mutation. Multiple logistical regression analyses indicated no correlation between ALDH2 genotype and the occurrence of restenosis after PCI (OR = 1.448, 95% CI: 0.965–2.168, p = 0.073), though a significant association was observed for patients with diabetes (OR = 4.053, 95% CI: 1.668–10.449, p = 0.003). Conclusion In this study, we found that carrying an ALDH2*2 allele had no notable relationship with ISR one year after PCI but that it did have a significant association with complications in diabetic patients. Further studies with larger sample sizes will be necessary to reveal a consensus. Electronic supplementary material The online version of this article (10.1186/s12872-019-1161-9) contains supplementary material, which is available to authorized users.

show abstract

Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting

Cited by 13 publications

References 30 publications

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

<p>Impacts of <em>CYP2C19</em> Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients</p>

Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention

Contact Info

Product

Resources

About